The B7 family subgroup reflects tumor cell heterogeneity and patient post-operative prognosis in gallbladder cancer
New genetic markers better predict outcomes in rare gallbladder cancer and identify a druggable pathway for future treatment development.
Single-cell RNA sequencing and a retrospective cohort (n=188) showed that B7-family checkpoint molecules delineate functionally distinct gallbladder cancer subpopulations, with HHLA2 promoting EMT via a druggable kinase pathway; a gradient-boosting ML model integrating these markers outperformed conventional staging for post-operative risk. GBC is a rare cancer with very poor prognosis and limited therapeutic options.
What the study was
- Study design
- scRNA-seq (7 primary tumors) + retrospective cohort (n=188 surgically treated GBC patients) + ML survival model (7 algorithms, GBM selected)
- Population
- Patients with gallbladder cancer (n=188) plus scRNA-seq exploratory cohort
- Sample size
- 188
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Biology Direct
Why it surfaced
Mechanistic novelty (HHLA2-RAC1/CDC42 axis) combined with ML-based staging improvement in a rare cancer with unmet need; requires prospective and multicenter validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.